Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study

被引：0
|
作者：
Cook, S.
Vermersch, P.
Comi, G.
Giovannoni, G.
Rammohan, K.
Rieckmann, P.
Sorensen, P. S.
Chang, P.
Hamlett, A.
Musch, B.
Viglietta, V.
Greenberg, S.
机构：
[1] Univ Med & Dent, Newark, NJ USA
[2] Univ Lille, Lille, France
[3] Univ Vita Salute, Milan, Italy
[4] Barts & London Queen Marys Sch Med & Dent, London, England
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[7] Rigshosp, DK-2100 Copenhagen, Denmark
[8] Merck Serono SA, Geneva, Switzerland
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [41] Safety and tolerability of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week Phase IIIb extension trial to the CLARITY study
    Cook, S.
    Comi, G.
    Rieckmann, P.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Martin, E.
    Dangond, F.
    Giovannoni, G.
    SWISS MEDICAL WEEKLY, 2016, 146 : 78S - 78S
  • [42] Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Hamlett, Anthony
    Scaramozza, Matthew
    Lachenal, Nathalie
    NEUROLOGY, 2013, 80
  • [43] Efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS) in the 120-week extension to the CLARITY study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensen, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP6 - NP7
  • [44] Cladribine improves relapsing-remitting MS: A double blind, placebo controlled study
    Sipe, JC
    Romine, JS
    Koziol, J
    Zyroff, J
    McMillan, R
    Beutler, E
    NEUROLOGY, 1997, 48 (03) : 45003 - 45003
  • [45] Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
    Calabresi, Peter A.
    Radue, Ernst-Wilhelm
    Goodin, Douglas
    Jeffery, Douglas
    Rammohan, Kottil W.
    Reder, Anthony T.
    Vollmer, Timothy
    Agius, Mark A.
    Kappos, Ludwig
    Stites, Tracy
    Li, Bingbing
    Cappiello, Linda
    von Rosenstiel, Philipp
    Lublin, Fred D.
    LANCET NEUROLOGY, 2014, 13 (06): : 545 - 556
  • [46] The efficacy of cladribine in relapsing-remitting multiple sclerosis: Clinical data from a randomized, double-blind, placebo-controlled, 18-month, phase II trial
    Sipe, Jack
    Gardner, Jason
    Beutler, Ernest
    NEUROLOGY, 2008, 70 (11) : A90 - A91
  • [47] CLARITY: an analysis of severity and frequency of relapses in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets or placebo
    Schippling, S.
    Sormani, M. P.
    De Stefano, N.
    Giovannoni, G.
    Galazka, A.
    Keller, B.
    Alexandri, N.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 258 - 259
  • [48] CLARITY: An Analysis of Severity and Frequency of Relapses in Patients with Relapsing-remitting Multiple Sclerosis Treated with Cladribine Tablets or Placebo
    Schippling, S.
    Sormani, M. P.
    De Stefano, N.
    Giovannoni, G.
    King, J.
    Galazka, A.
    Keller, B.
    Alexandri, N.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 466 - 467
  • [49] Exploring correlations between changes in lymphocyte counts and clinical/magnetic resonance imaging outcomes in cladribine-treated patients with relapsing-remitting multiple sclerosis: analyses from the double-blind, 96-week CLARITY study
    Rieckmann, P.
    Sorensen, P. Soelberg
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Vermersch, P.
    Kurukulasuriya, N.
    Bock, D.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 48 - 48
  • [50] Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial
    Rahimlou, Mehran
    Nematollahi, Shima
    Husain, Durdana
    Banaei-Jahromi, Nasrin
    Majdinasab, Nastaran
    Hosseini, Seyed Ahmad
    FRONTIERS IN NEUROSCIENCE, 2022, 16
12345